News

Multiple cancers is a risk factor for a poorer prognosis in SM.

New study reveals rising U.S. rates of systemic mastocytosis and increased risk of secondary cancers, especially in older adults.

A clinical trial of 16 patients with indolent SM found that sarilumab does not significantly improve quality of life.

A man with acute myeloid leukemia was also diagnosed with systemic mastocytosis after late bone marrow tests.

Tryptase genotyping helps determine whether a high tryptase level reflects disease or genetics in systemic mastocytosis (SM).

A recent case study highlights how anemia and low platelet counts can be the initial presentation of systemic mastocytosis (SM).

Patients with systemic mastocytosis (SM) face significantly increased risks of melanoma and other skin cancers.

A recently published case report highlighted systemic mastocytosis (SM) as a possible cause of chronic diarrhea.

HT-KIT cut KIT protein levels by more than 80% and halted tumor growth in systemic mastocytosis (SM) models.

Relying on BST levels to diagnose SM doesn’t account for individual variability influenced by genetic and physiological factors.